NHS England's March 2024 commissioning policy ending routine NHS prescription of puberty blockers to under-18s for gender dysphoria, following the Cass Review. Blockers thereafter only within the planned clinical trial.
Puberty suppressing hormones (PSH) are not available as a routine commissioning treatment option for children and young people who have gender incongruence or gender dysphoria.
NHS England's March 2024 commissioning policy ending routine NHS prescription of puberty blockers to under-18s for gender dysphoria, following the Cass Review. Blockers thereafter only within the planned clinical trial.